The U.S.’s woefully low COVID vaccination rate makes it Novavax’s most appealing market yet

The CDC approved Novavax’s COVID vaccine on Tuesday, and investors sent Novavax’s stock up 11.5% Read More



Source link

Leave a Reply

Your email address will not be published.